Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose

Exclusion Criteria

• •Patients with any concomitant clinical condition that, according to the investigator's opinion, might impede an adequate assessment of the treatment response.
• •Patients with severe hyperparathyroidism (PTH\>3000pg/mL).
• •Patients with a serum calcium level greater or equal to 10.5mg/dL, phosphorus greater or equal to 6.5mg/dL, or those with Calcium X Phosphorus product 65 (measured at least 2 weeks before the study).
• •Patients with neoplastic disease.
• •Pregnant or lactating women.
• •Known hypersensitivity and/or toxicity to vitamin D metabolites and/or to other ingredients of the product.
• •Having participated in another study with an investigational product or device within the previous 30 days or having planned to participate in another study within the same period of time as the actual study.
• •Use of vitamin D analogue during the last 3 months prior to the inclusion to this study.